Literature DB >> 10954045

The decrease of mitochondrial NADH dehydrogenease and drug induced apoptosis in doxorubicin resistant A431 cells.

T W Wong1, H Y Yu, S K Kong, K P Fung, T T Kwok.   

Abstract

Doxorubicin (DOX) resistant A10A cells derived from human squamous carcinoma A431 cells were found to exhibit a smaller degree of apoptosis after DOX treatment as compared to their parent cells. Induction of reactive oxygen species (ROS) formation and mitochondrial depolarization by DOX were more pronounced in the parent cells than in the A10A cells. The fact that catalase suppressed the DOX effect on ROS induction, mitochondrial depolarization and apoptosis in both cell lines suggests an involvement of ROS in the DOX-induced apoptosis. To investigate the underlying mechanisms for DOX resistance in A10A cells, RT-PCR based differential display was used. One of the clones, which was down-regulated in the A10A cells, had sequence homology with part of the mitochondrial NADH dehydrogenase III (ND3) gene. NADH dehydrogenase plays an important role in generating ROS during DOX treatment. The results indicate that down-regulation of ND3 may at least in part contribute to the mechanism for A10A cells resistant to DOX-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954045     DOI: 10.1016/s0024-3205(00)00699-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress.

Authors:  M Benhar; I Dalyot; D Engelberg; A Levitzki
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

2.  A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

Authors:  Claudia Arce; Carlos Pérez-Plasencia; Aurora González-Fierro; Erick de la Cruz-Hernández; Alma Revilla-Vázquez; Alma Chávez-Blanco; Catalina Trejo-Becerril; Enrique Pérez-Cárdenas; Lucia Taja-Chayeb; Enrique Bargallo; Patricia Villarreal; Teresa Ramírez; Teresa Vela; Myrna Candelaria; Maria F Camargo; Elizabeth Robles; Alfonso Dueñas-González
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

3.  Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3.

Authors:  Tomoyoshi Komiyama; Atsushi Ogura; Takatsugu Hirokawa; Miao Zhijing; Hiroshi Kamiguchi; Satomi Asai; Hayato Miyachi; Hiroyuki Kobayashi
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

Review 4.  Doxorubicin-Induced Cognitive Impairment: The Mechanistic Insights.

Authors:  Jiajia Du; Aoxue Zhang; Jing Li; Xin Liu; Shuai Wu; Bin Wang; Yanhong Wang; Hongyan Jia
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

5.  Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib.

Authors:  Ewelina Synowiec; Grazyna Hoser; Jolanta Bialkowska-Warzecha; Elzbieta Pawlowska; Tomasz Skorski; Janusz Blasiak
Journal:  Biomed Res Int       Date:  2015-11-04       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.